周三，Jones Trading 开始对 ORIC Pharmaceuticals (NASDAQ: ORIC) 进行覆盖，给予买入评级，目标价为17.00美元。该公司的分析突出了 ORIC 专注于开发针对非小细胞肺癌（NSCLC）和转移性前列腺癌的靶向治疗药物，并指出公司经验丰富的管理团队此前在 Ignyta 公司成功开发了 entrectinib。

Live webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the ...

Fintel reports that on October 31, 2024, Jones Trading initiated coverage of ORIC Pharmaceuticals (NasdaqGS:ORIC) with a Buy ...

About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report) today and set a price ...

About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.ORIC’s clinical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) have earned an average rating of “Buy” from the eight brokerages that are presently covering the firm, Marketbeat.com reports.

Last week, we published a light-hearted article about a PS Plus user who stacked Premium subscription for nearly a quarter of ...

ORIC Pharmaceuticals (ORIC) announced the company presented a poster highlighting certain best-in-class properties of ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...